Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease

被引:115
作者
Petta, S. [1 ]
Amato, M. C. [2 ]
Di Marco, V. [1 ]
Camma, C. [1 ]
Pizzolanti, G. [2 ]
Barcellona, M. R. [1 ]
Cabibi, D.
Galluzzo, A. [2 ]
Sinagra, D. [2 ]
Giordano, C. [2 ]
Craxi, A. [1 ]
机构
[1] Univ Palermo, DiBi MIS, Sez Gastroenterol, Palermo, Italy
[2] Univ Palermo, DiBi MIS, Sez Endocrinol, Palermo, Italy
关键词
CHRONIC HEPATITIS-C; INSULIN-RESISTANCE; TNF-ALPHA; BODY-FAT; STEATOHEPATITIS; PROGRESSION; RISK; ACCUMULATION; ADIPONECTIN; RECEPTORS;
D O I
10.1111/j.1365-2036.2011.04929.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Metabolic factors have been associated with liver damage in patients with non-alcoholic fatty liver disease (NAFLD). Aims To test a new marker of adipose dysfunction, the visceral adiposity index (VAI), in NAFLD patients to assess whether or not it is associated with host factors, and to investigate a potential correlation with histological findings. Methods One hundred and forty-two consecutive NAFLD patients were evaluated by liver biopsy, and clinical and metabolic measurements, including insulin resistance with the homeostasis model assessment (HOMA), and VAI by using waist circumference, body mass index, triglycerides and HDL. Serum levels of TNFa, IL-6, adiponectin and leptin were also assessed. All biopsies were scored for NAFLD activity score (NAS) and its components, and for staging (Kleiner). Results By multiple linear regression analysis, VAI was independently associated with higher HOMA (P = 0.04), and fibrosis (P = 0.04). In addition, an independent association was found between higher VAI and lower adiponectin levels (P = 0.002). Higher HOMA (OR 1.149, 95% CI 1.0031.316, P = 0.04), higher VAI (OR 1.446, 95% CI 1.0232.043, P = 0.03), lobular inflammation (OR 3.777, 95% CI 1.7718.051, P = 0.001), and ballooning (OR 2.884, 95% CI 1.2316.757, P = 0.01) were correlated with significant fibrosis (F2F4) on multiple logistic regression analysis. In particular, the prevalence of significant fibrosis progressively increased from patients with a VAI = 2.1 and HOMA = 3.4 (26%) to those with a VAI > 2.1 and HOMA > 3.4 (83%). Conclusions In NAFLD patients, visceral adiposity index is an expression of both qualitative and quantitative adipose tissue dysfunction and, together with insulin resistance, is independently correlated with significant fibrosis.
引用
收藏
页码:238 / 247
页数:10
相关论文
共 37 条
[1]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[2]   Visceral Adiposity Index A reliable indicator of visceral fat function associated with cardiometabolic risk [J].
Amato, Marco C. ;
Giordano, Carla ;
Galia, Massimo ;
Criscimanna, Angela ;
Vitabile, Salvatore ;
Midiri, Massimo ;
Galluzzo, Aldo .
DIABETES CARE, 2010, 33 (04) :920-922
[3]  
[Anonymous], 1992, SAS STAT SOFTW CHANG
[4]   Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis [J].
Argo, Curtis K. ;
Northup, Patrick G. ;
Al-Osaimi, Abdullah M. S. ;
Caldwell, Stephen H. .
JOURNAL OF HEPATOLOGY, 2009, 51 (02) :371-379
[5]   Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis [J].
Bugianesi, Elisabetta ;
Marchesini, Gulio ;
Gentilcore, Elena ;
Cua, Ian Homer Y. ;
Vanni, Ester ;
Rizzetto, Mario ;
George, Jacob .
HEPATOLOGY, 2006, 44 (06) :1648-1655
[6]   Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men [J].
Chan, D. C. ;
Watts, G. F. ;
Ng, T. W. K. ;
Hua, J. ;
Song, S. ;
Barrett, P. H. R. .
DIABETES OBESITY & METABOLISM, 2006, 8 (06) :698-702
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease [J].
Colloredo, G ;
Guido, M ;
Sonzogni, A ;
Leandro, G .
JOURNAL OF HEPATOLOGY, 2003, 39 (02) :239-244
[9]   Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients [J].
Crespo, J ;
Cayón, A ;
Fernández-Gil, P ;
Hernández-Guerra, M ;
Mayorga, M ;
Domínguez-Díez, A ;
Fernández-Escalante, JC ;
Pons-Romero, F .
HEPATOLOGY, 2001, 34 (06) :1158-1163
[10]   Abdominal obesity and metabolic syndrome [J].
Despres, Jean-Pierre ;
Lemieux, Isabelle .
NATURE, 2006, 444 (7121) :881-887